Pharmigene Licenses IP to Mayo Clinic for Companion Dx for Stevens-Johnson Syndrome

The Mayo Clinic will develop tests to detect for the presence of alleles that increase the risk for developing the potentially deadly skin disease if certain drugs are taken.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.